Program Committee Biographies
Ahti Anttila is Research Director of the Mass Screening Registry of the Finnish Cancer Registry. Principal investigator in the evaluation of the Finnish cervical and breast cancer screening programs at the Mass Screening Registry.
Marc Arbyn obtained his MD diploma in 1984 at the University of Ghent (Belgium); he obtained diplomas of Dr in tropical medicine and a MSc degree in tropical epidemiology at the Institute of Tropical Medicine in Antwerp.
Dr. Johannes (Hans) Berkhof is head of the biostatistics unit of the VU University Medical Centre (VUMC) Amsterdam and has 15 years expertise in statistical and modelling research.
Paolo Bonanni graduated in Medicine and Surgery (MD) in 1985 and got two specializations in Hygiene and Preventive Medicine at the University of Genoa, Italy.
Professor Jacob Bornstein MD, MPA, is the Chairman of the Department of Obstetrics and Gynecology in Galilee Medical Center-Nahariya, Israel. He is Full Professor and Associate Dean at the Bar-Ilan University, Faculty of Medicine.
Xavier Bosch - Cancer epidemiologist and oncologist. Contributions to the research leading to the identification of the causal role of HPV in cervical cancer, international HPV type distributions in lesions and HPV impact on other cancers.
Ruud H. Brakenhoff, PhD is molecular biologist at the Tumor Biology section of the Department of Otolaryngology-Head and Neck Surgery of the VU University Medical Center, Amsterdam, the Netherlands.
Dr Marc Brisson is an associate professor at Laval University where he holds a Canada Research Chair in Mathematical Modeling and Health Economics of Infectious Diseases.
Dr Julia Brotherton is a public health physician and Medical Director of Australia’s National HPV Vaccination Program Register.
Dr. Barbara Burtness is a medical oncologist at the Yale Cancer Center, where she co-leads the Developmental Therapeutics program and the Translational Working Group for head and neck cancer.
Francesca Maria Carozzi is Biologist. She has worked from 1989 at the Centro per lo Studio e la Prevenzione Oncologica of Florence in department of Molecular Unit.
Dr. Castellsagué’s academic background includes a Medical Degree, a specialization in Preventive Medicine and Public Health, a Master of Public Health, and a Ph.D. in Epidemiology and Public Health.
Dr Gary Clifford, born in Brighton, UK in 1973, obtained his PhD in biological sciences at the University of Newcastle upon Tyne, UK.
Heather Cubie is a Consultant Clinical Scientist with an Honorary Chair in the University of Edinburgh College of Medicine and Veterinary Medicine.
Jack Cuzick is:
Director – Wolfson Institute of Preventive Medicine Head, CRUK Centre for Cancer Prevention
Tina Dalianis MD 1974, PhD 1980 Karolinska Institutet (KI), post doc 1987-1989 at NIMR, London, UK, became specialist in Clinical Virology 1991 and Clinical Immunology 1995 and was 1995-2000 head of the Section of Transplantation Immunology, Huddinge Hospital.
Dr. Silvia de Sanjosé received her Medical degree (University of Barcelona, Spain 1980); Specialized in Family practice (University of Barcelona, Spain 1983); Master of Science in Epidemiology (London School of Hygiene and Tropical Medicine, University of London (1986);
Joakim Dillner is professor in infectious disease epidemiology at Karolinska Institutet. His research is focused on cancer screening and tumor virology, especially human papillomavirus (HPV).
John Doorbar has studied Human Papillomaviruses and the life-cycle of HPV's for many years, and currently has interests in viral tropisms, latency and the different strategies used by the high and low-risk papillomavirus types.
Mark H. Einstein, MD, MS, FACOG, FACS Professor and Vice Chair for Research, Department of Obstetrics & Gynecology and Women’s Health at the Albert Einstein College of Medicine and Montefiore Medical Center.
Miriam Elfström’s background is in public health and she is currently working at the Karolinska Institute in Stockholm, Sweden.
Dr. Carole Fakhry is a head and neck oncologic surgeon with a research focus in HPV and head and neck cancer.
Prof Alison Fiander took up the Chair of Obstetrics and Gynaecology, Cardiff University in 2002. She developed a programme of research investigating Human Papillomavirus infection:
Dr Silvia Franceschi, Special Advisor and Head, Infections and Cancer Epidemiology Group, International Agency for Research on Cancer, Lyon, France:
Dr. Franco is Professor and Chair, Department of Oncology, and Director, Division of Cancer Epidemiology, McGill University, Montreal, Canada.
Dr. Anna Giuliano is the founding Director of the Center for Infection Research in Cancer (CIRC) at the Moffitt Cancer Center and is an expert in this field with a long and successful record of NIH funding.
Professor Suzanne Garland is an internationally recognized clinical microbiologist and sexual health physician, with particular expertise in infectious diseases as they pertain to reproductive health and the neonate.
Dr. Goodman’s research focus is on the natural history of human papillomavirus-related anogenital disease and the identification of cofactors in viral persistence;
Dr. Gravitt is a molecular epidemiologist whose research in human papillomavirus and cervical cancer spans the translational spectrum from natural history to global cervical prevention.
Christine Haie-Meder is Head of the Brachytherapy Service since November 1rst 1999.
Danielle A.M. Heideman gained her MSc degree in Medical Biology cum laude in 1998, and holds a PhD degree from VU University Amsterdam, the Netherlands.
Peter Hillemanns, MD, is a Professor of Obstetrics and Gynecology and serves as Chairman of the Dept. of Obstetrics, Gynecology, and Breast Cancer Center at Medical University Hannover, Germany.
Professor Thomas Iftner graduated in Biology/Virology and did his postgraduate research fellowship at the University of California, Los Angeles.
Mark Jit is senior scientist in the Modelling and Economics Unit of Public Health England (PHE) and senior lecturer in vaccine epidemiology at the London School of Hygiene and Tropical Medicine (LSHTM).
Elmar A. Joura, M.D., is Associate Professor of Gynecology and Obstetrics at the Medical University of Vienna, General Hospital (AKH), and Comprehensive Cancer Center Vienna, Austria.
Dr. Kaufmann holds a position as head of research at the Clinic for Gynaecology of the Charité-Universitätsmedizin Berlin, Germany.
Walter Kinney is a Gyn Oncologist who is also Board Certified in Internal Medicine, and practices in The Permanente Medical Group.
Aimée R. Kreimer is an Investigator in the Division of Cancer Epidemiology and Genetics at the National Cancer Institute (NCI) and focuses her research on the etiology and prevention of humanpapillomavirus associated cancers of the head and neck and anogenital sites.
Dr. Kulasingam is an Associate Professor in the Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Twin Cities.
Charles JN Lacey is Professor of Medicine (Genitourinary Medicine) at Hull York Medical School (HYMS), University of York (UoY), one of the PIs at the Centre for Immunology and Infection (CII),
Lisa Licitra is Board-certified in medical oncology, with special expertise in the treatment of head and neck cancers..
Pier Luigi Lopalco, MD, Professor of Hygiene and Preventive Medicine at the University of Bari (Italy). In 2005 he joined the ECDC, where is Head of the Scientific Assessment Section.
Attila Lorincz discovered and cloned several important and novel carcinogenic HPV types, including HPV31, HPV35, HPV45, HPV52 and HPV56, and pioneered the initial use of HPV DNA testing for clinical diagnostics.
Hisham Mehanna is the Chair of Head and Neck Surgery, University of Birmingham and a consultant head and neck and thyroid surgeon, at the University Hospitals Birmingham and Heart of England Hospital, Birmingham.
Chris Meijer is MD (Leiden 1972), PhD (Amsterdam 1971), and surgical pathologist (Leiden, since 1977) with a strong interest in immunology and molecular biology.
Dr. Moscicki is currently Professor of Pediatrics at UCSF, Associate Director, Division of Adolescent Medicine and Vice-Chair Department of Pediatrics, Clinical and Translation Research.
Alan G. Nyitray is an assistant professor studying HPV in men with a focus on the natural history of anal HPV infection and anal cancer.
Dr. Pai is an Associate Professor of Surgery at Massachusetts General Hospital and Harvard Medical School.
Julian Peto (Cancer Research UK Chair of Epidemiology, London School of Hygiene & Tropical Medicine) studied maths before becoming a medical statistician.
Mario Poljak, MD, PhD, specialist in clinical microbiology is Professor of Microbiology and Immunology and Head of Laboratory for Molecular Microbiology
Doctor Sally Roberts is senior lecturer at the University of Birmingham. Her research portfolio focuses on understanding the molecular biology of human papillomaviruses (HPV) life cycle and the contribution of virus-host interactions to the development of cancer.
Dr. Romanowski is a Clinical Professor in the Division of Infectious Diseases, University of Alberta. She was Director of the Alberta STD Program from 1979 to 1998.
Doctor Michel Roy is Professor of Gynecology at Laval University. He was successively Chairman of the Department of Obstetrics and Gynecology at Laval University, and Head of the division of Gynecologic Oncology in the same department.
Dr. Safaeian received a Ph.D. in Infectious Disease Epidemiology from the Johns Hopkins Bloomberg School of Public Health in 2006.
Rengaswamy Sankaranarayanan, MD
After working in clinical oncology and cancer control in India, Dr Sankaranarayanan joined the International Agency for Research on Cancer (Cancer Research agency of the WHO) in 1993,
Professor Albert Singer
Academic and clinical interest in the cervix and lower genital tract for many years .
Jennifer S. Smith is an Associate Professor in the Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina.
Dr. Peter Snijders gained his degree in biology in 1987 from the Catholic University in Nijmegen. He holds a doctoral degree in Medicine from VU University in Amsterdam.
Professor Stanley is Professor of Epithelial Biology and Director of Research in the University of Cambridge Honorary Consultant Addenbrookes Hospital Cambridge and Fellow of Christs College.
A family practitioner, Dr Steben is medical advisor at the STI unit of Quebec’s National Public Health Institute. He chairs Québec province committee on STI and member of the STI laboratory analysis committee.
Professor Peter L Stern is at the Institute of Cancer Studies, Paterson Building, University of Manchester, UK. He trained at University College, London, UK, obtaining his BSc and PhD.
Dr. Mark H. Stoler is Professor (Emeritus) of Pathology and Clinical Gynecology at the University of Virginia Health System, Charlottesville.
Dr Massimo Tommasino is Head of the Infections Section and of the Infections and Cancer Biology Group at the International Agency for Research on Cancer (IARC) in Lyon, France.
Sjoerd H. van der Burg, Ph.D. is a professor in the immunotherapy of cancer, with a special emphasis on immunomonitoring at the department of clinical oncology of the Leiden University Medical Center